Phathom Pharmaceuticals (PHAT) Equity Average: 2022-2025
Historic Equity Average for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -$414.2 million.
- Phathom Pharmaceuticals' Equity Average fell 96.79% to -$414.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$414.2 million, marking a year-over-year decrease of 96.79%. This contributed to the annual value of -$163.2 million for FY2024, which is 121.14% down from last year.
- As of Q3 2025, Phathom Pharmaceuticals' Equity Average stood at -$414.2 million, which was down 11.31% from -$372.1 million recorded in Q2 2025.
- Phathom Pharmaceuticals' 5-year Equity Average high stood at $15.5 million for Q2 2022, and its period low was -$414.2 million during Q3 2025.
- Its 3-year average for Equity Average is -$179.9 million, with a median of -$191.2 million in 2024.
- In the last 5 years, Phathom Pharmaceuticals' Equity Average surged by 99.48% in 2023 and then crashed by 243,218.50% in 2024.
- Over the past 4 years, Phathom Pharmaceuticals' Equity Average (Quarterly) stood at -$50.6 million in 2022, then grew by 10.57% to -$45.3 million in 2023, then plummeted by 386.78% to -$220.3 million in 2024, then plummeted by 96.79% to -$414.2 million in 2025.
- Its Equity Average was -$414.2 million in Q3 2025, compared to -$372.1 million in Q2 2025 and -$296.0 million in Q1 2025.